Category: IP Practice in India

Growing Significance & Relevance of Shadow Counsels

23rd June, 2018 - 12:52 pm Categories: IP Practice in India

Shadow Counsels (SC) are not a concept popularly exploited in India. However, their potential is yet to be discovered and realized in order for it to be part of our customary practice. The term ‘Shadow Counsel’ is used for any alternate or auxiliary lawyer appointed in case the original lawyer or the main counsel falters … Continue reading Growing Significance & Relevance of Shadow Counsels

Read more »

SUMMARY JUDGMENT IN INTELLECTUAL PROPERTY DISPUTES UNDER ORDER XIII-A OF CIVIL PROCEDURE CODE

24th July, 2017 - 4:59 am Categories: India Intellectual Property IP Litigation IP Practice in India

Applicability of order XIII-A of CPC to Intellectual Property Dispute With the objective of streamlining and expediting the disposal of disputes in litigation, the Commercial Courts, Commercial Division and Commercial Appellate Division of High Courts Act, 2015 (hereinafter referred to as the “Act”) came into effect on October 23, 2015. The Act provides for the … Continue reading SUMMARY JUDGMENT IN INTELLECTUAL PROPERTY DISPUTES UNDER ORDER XIII-A OF CIVIL PROCEDURE CODE

Read more »

Delhi High Court sought Explanation through Counter Affidavit over Repudiation of Patent application for Xtandi

8th April, 2017 - 6:11 am Categories: India Intellectual Property IP Practice in India News & Updates Patents

Xtandi, the wonder drug for prostate cancer, was developed at UCLA, Los Angeles, by the innovation of NIH and Department of Defense grants. The drug was later licensed to Medivation, a biopharma company, which in October 2009 struck a deal with Japanese Astellas Pharma to collaborate on developing and commercializing Xtandi. The two companies now … Continue reading Delhi High Court sought Explanation through Counter Affidavit over Repudiation of Patent application for Xtandi

Read more »

Fighting with Counterfeit Menace: Montblanc Simplo GmbH vs. Gaurav Bhatia & ors. CS(OS) 2563/2013: Granting Injunctive Relief

21st March, 2017 - 7:38 am Categories: India IP Practice in India News & Updates Trademark

Introduction: It always has been a well known fact that the markets in India are targeted by large number of counterfeit products/goods. Popular brands like LV, GUCCI, Burberry, Armani, Hermes inter alia; are frequently pirated in local commercial markets. Among others, the most popular counterfeit products in market include hardware, software, clothing, watches, writing instruments. … Continue reading Fighting with Counterfeit Menace: Montblanc Simplo GmbH vs. Gaurav Bhatia & ors. CS(OS) 2563/2013: Granting Injunctive Relief

Read more »

Export under section 107A of Indian Patent Act, 1970

11th March, 2017 - 11:03 am Categories: India IP Practice in India Licensing News & Updates

In the case of Bayer Corporation versus Union of India & ors (W.P.(C) 1971/2014) and Bayer Intellectual Property Gmbh & Anr versus Alembic Pharmaceuticals ltd (CS(COMM) No.1592/2016), High Court of Delhi in the consolidated decision dated March 08, 2017, adjudicated on the issue whether Section 107A of the Patents Act, 1970 permits export from India … Continue reading Export under section 107A of Indian Patent Act, 1970

Read more »

India’s time to delve into IP laws

9th March, 2017 - 6:43 am Categories: Copyright India IP Practice in India News & Updates Patents Trademark

Shireen Shukla, legal intern at Kkurana & Khurana, probes the recent International IP Index report, released by U.S. Chamber of Commerce, where India stood at 43rd position, out of 45 countries. On 8th February, 2017 U.S. Chamber of Commerce released its 5th annual International IP Index, “The Roots of Innovation,” rating 45 world economies on patents, … Continue reading India’s time to delve into IP laws

Read more »

Effect of Union Budget, 2017 on the R&D/ Intellectual Property Practices in India

13th February, 2017 - 5:43 am Categories: India IP Practice in India News & Updates

Union budget that was highly waited for (after demonetization) had gained more attention also due to preponing to February 01, 2017. As a matter of fact, every year budget has certain impact on various industries including IP industry and R&D sectors. In this article, we will try to analyze possible effects of 2017 budget on … Continue reading Effect of Union Budget, 2017 on the R&D/ Intellectual Property Practices in India

Read more »

Foreign Filing Permission: Indian Patent System Perspective

27th December, 2016 - 6:16 am Categories: India IP Practice in India Patents

Different countries having regard to National Security Considerations and with the intent of having a check on the defence and atomic energy related inventions, have different restrictions in place. While some countries make it mandatory to file Patent Applications in their country before applying in any other country, some countries require only prior permission before … Continue reading Foreign Filing Permission: Indian Patent System Perspective

Read more »

Hetero’s Subsidiaries not infringing Roxane’s patent on PhosLo

14th December, 2016 - 6:56 am Categories: Hi Tech Patent Litigation India IP Practice in India News & Updates Patent Litigation Patents

In Roxane Laboratories, Inc. (hereinafter referred to be as “Roxane”) v. Camber Pharmaceuticals Inc., et al. (hereinafter referred to as “Camber”) decided by United States Court of Appeals for the Federal Circuit on November 17, 2016, Roxane had appealed against decision of district court in an infringement suit against Camber and Invagen Pharmaceuticals Inc (collectively … Continue reading Hetero’s Subsidiaries not infringing Roxane’s patent on PhosLo

Read more »

Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

27th July, 2015 - 5:47 am Categories: India IP Practice in India News & Updates Patents pharma

Lee Pharma, a Hyderabad-based Indian pharma company, has filed a Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the patented drugs Saxagliptin for treating Diabetes Mellitus. The Patent on Saxagliptin was granted to Bristol Myers Squibb (BMS) in India on 30th April 2007 having number IN … Continue reading Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

Read more »

Categories

Archives